Chinese Scientists Use E Coli to Fight Breast Tumours From Within in Mice Study

Why It Matters

This bacterial delivery system could transform chemotherapy by concentrating treatment inside tumors, minimizing harmful side effects and improving patient outcomes, signaling a new direction for precision oncology.

Key Takeaways

• Engineered E. coli Nissle 1917 produces Romidepsin inside tumors
• Bacterial colonization targets breast cancer with reduced systemic toxicity
• Four strains matched drug efficacy; one outperformed standard treatment
• Mice receiving engineered bacteria showed lower mortality than drug alone
• Approach demonstrates live‑vector platform for future solid‑tumor therapies

Pulse Analysis

Bacterial vectors have long intrigued oncologists seeking more precise drug delivery, and the probiotic strain Escherichia coli Nissle 1917 (EcN) is emerging as a leading candidate. Originally isolated for its gut‑friendly properties, EcN naturally homes to hypoxic tumor niches, making it an ideal carrier for therapeutic payloads. Recent advances in synthetic biology enable researchers to program these microbes to manufacture complex molecules on site, bypassing the need for high systemic doses that often cause collateral damage.

In the latest pre‑clinical trial, a team from Shandong University re‑engineered EcN to produce Romidepsin, an FDA‑approved histone deacetylase inhibitor traditionally used for lymphoma. When injected into mice bearing breast‑cancer xenografts, the modified bacteria proliferated within the tumor microenvironment and released the drug directly where it was needed. Four of the engineered strains achieved tumor suppression on par with conventional Romidepsin administration, while a fifth demonstrated superior efficacy with markedly lower toxicity. Importantly, mice treated with the bacterial platform exhibited reduced mortality compared with those receiving the drug alone, underscoring the safety advantage of localized delivery.

The implications extend beyond a single drug or cancer type. By turning benign microbes into programmable factories, the approach could democratize access to high‑value biologics and enable combination therapies that are difficult to achieve with traditional pharmacology. However, translating these findings to humans will require rigorous safety profiling, regulatory navigation, and scalable manufacturing processes. If these hurdles are cleared, bacterial‑based tumor targeting could reshape the oncology market, offering a cost‑effective, patient‑centric alternative to systemic chemotherapy.